A number of anti-cancer drugs have been developed that target the kinase domain of HER2. These drugs work by inhibiting the activity of HER2, which prevents the cancer cells from growing and dividing. However, some of these drugs can also interact with other drugs and biomolecules, which can lead to adverse effects or reduced efficacy.